Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Shares Outstanding (Weighted Average): 2014-2024

Historic Shares Outstanding (Weighted Average) for ImmunityBio (IBRX) over the last 11 years, with Dec 2024 value amounting to $696.8 million.

  • ImmunityBio's Shares Outstanding (Weighted Average) rose 35.71% to $945.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $945.3 million, marking a year-over-year increase of 35.71%. This contributed to the annual value of $696.8 million for FY2024, which is 4.36% up from last year.
  • As of FY2024, ImmunityBio's Shares Outstanding (Weighted Average) stood at $696.8 million, which was up 4.36% from $667.7 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Shares Outstanding (Weighted Average) ranged from a high of $696.8 million in FY2024 and a low of $108.6 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $667.7 million (2023), whereas its average is $588.3 million.
  • Data for ImmunityBio's Shares Outstanding (Weighted Average) shows a peak YoY spiked of 266.13% (in 2021) over the last 5 years.
  • Over the past 5 years, ImmunityBio's Shares Outstanding (Weighted Average) (Yearly) stood at $108.6 million in 2020, then spiked by 266.13% to $397.6 million in 2021, then increased by 0.68% to $400.3 million in 2022, then skyrocketed by 66.80% to $667.7 million in 2023, then climbed by 4.36% to $696.8 million in 2024.